Evidence map›Paper›PMID 26123358›Full record

ReviewStem cell reviews and reports2015

Practical Issues with the Use of Stem Cells for Cancer Gene Therapy.

Faranak Salman Nouri, Debabrata Banerjee, Arash Hatefi

Abstract readReview
In one paragraph

Review in Stem cell reviews and reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Enzyme/Prodrug Systems for Cancer Gene Therapy.Current pharmacology reports · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Faranak Salman NouriDepartment of Pharmaceutics, Rutgers, The State University of New Jersey, William Levine Hall, Room 222, 160 Frelinghuysen Road, Piscataway, NJ, 08854, USA.
Debabrata Banerjee
Arash Hatefi

Funding

A Nanotechnology Platform for Suicide Gene Therapy of Recurring Ovarian CancerR01CA175318 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI HATEFI, ARASH · 2015 to 2019
$1.8M
Bioengineering a Safe and Efficient Vector Technology for Stem Cell TransfectionR21EB016792 · NIBIB · RUTGERS, THE STATE UNIV OF N.J. · PI HATEFI, ARASH · 2014 to 2015
$426k
NCI NIH HHS R01 CA175318NCI NIH HHS R01CA175318NIBIB NIH HHS R21 EB016792NIBIB NIH HHS R21EB016792
6 · The paper itself

Abstract

Stem cell-based drug delivery for cancer therapy has steadily gained momentum in the past decade as several studies have reported stem cells' inherent tropism towards tumors. Since this science is still in its early stages and there are many factors that could significantly impact tumor tropism of stem cells, some contradictory results have been observed. This review starts by examining a number of proof-of-concept studies that demonstrate the potential application of stem cells in cancer therapy. Studies that illustrate stem cells' tumor tropism and discuss the technical difficulties that could impact the therapeutic outcome are also highlighted. The discussion also emphasizes stem cell imaging/tracking, as it plays a crucial role in performing reliable dose-response studies and evaluating the therapeutic outcome of treatment protocols. In each section, the pros and cons associated with each method are highlighted, limitations are underlined, and potential solutions are discussed. The overall intention is to familiarize the reader with important practical issues related to stem cell cancer tropism and in vivo tracking, underline the shortcomings, and emphasize critical factors that need to be considered for effective translation of this science into the clinic.

Indexed as

AnimalsDrug Delivery SystemsGenetic TherapyHumansNeoplasmsStem CellsTropism

Identifiers

PMID26123358
PMCPMC4758683

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.